Evolution of Anti-SARS-CoV-2 Humoral Immunity Following COVID-19 Infection among Vaccinated and Previously Infected Healthcare Workers in Côte d’Ivoire — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Evolution of Anti-SARS-CoV-2 Humoral Immunity Following COVID-19 Infection among Vaccinated and Previously Infected Healthcare Workers in Côte d’Ivoire
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Alassane Ouattara University, Bouaké, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Alassane Ouattara University, Bouaké, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
,
Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
1 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
2 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
3 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
4 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
5 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Alassane Ouattara University, Bouaké, Côte d’Ivoire
6 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
7 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Alassane Ouattara University, Bouaké, Côte d’Ivoire
8 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
9 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
10 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
11 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
12 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
13 Immunology and Allergology Department, Medical Sciences Training and Research Unit, Félix Houphouët-Boigny University, Abidjan, Côte d’Ivoire
Background: Coronavirus disease (or COVID-19), caused by the novel coronavirus SARS-CoV-2, the most virulent identified to date, remains a major global public health challenge. Given the essential role of specific anti-SARS-CoV-2 humoral immunity in protection against reinfection, it is crucial to characterize its kinetics to adapt vaccination strategies. This longitudinal study aimed to evaluate the kinetics of anti-SARS-CoV-2 IgG and neutralizing antibodies produced by previously immunized subjects in response to new infection over 28 days within a cohort of 36 healthcare workers diagnosed with COVID-19 in Côte d’Ivoire. Methods: Between April and June 2022, healthcare professionals infected with COVID-19 were recruited from three university hospitals in Abidjan. Serum samples were collected, and anti-Spike IgG and neutralizing antibodies were quantified using a competitive enzyme immunoassay (Chorus TRIO, DIESSE). Both antibody types were evaluated at days 0, 7, 14, 21, and 28 following diagnosis. Results: IgG levels increased significantly over time (p < 0.0001), whereas neutralizing antibodies showed no significant variation. At diagnosis, residual IgG titres were higher in previously infected individuals, while neutralizing antibody levels were higher among vaccinated subjects and those with hybrid immunity. Upon reinfection, antibody production was enhanced in these groups. The higher IgG levels in previously infected individuals compared to vaccinated ones suggest a stronger booster effect when the same mode of immunization is maintained. Overall, IgG levels tended to rise progressively, contrasting with a decline in neutralizing antibodies, which typically occurred after a peak at day 14. Conclusion: IgG levels gradually increased, while neutralizing antibody titres declined after peaking on day 14.
Efrati, S., Catalogna, M., Abu Hamad, R., Hadanny, A., Bar-Chaim, A., Benveniste-Levkovitz, P., et al . (2021) Safety and Humoral Responses to BNT162b2 mRNA Vaccination of SARS-CoV-2 Previously Infected and Naive Populations. Scientific Reports , 11, Article No. 16543. https://doi.org/10.1038/s41598-021-96129-6
Guzmán-Martínez, O., Guardado, K., Varela-Cardoso, M., Trujillo-Rivera, A., Marín-Hernández, A., Ortiz-León, M.C., et al . (2021) Generation and Persistence of S1 IgG and Neutralizing Antibodies in Post-Covid-19 Patients. Infection , 50, 447-456. https://doi.org/10.1007/s15010-021-01705-7
Ren, X., Zhou, J., Guo, J., Hao, C., Zheng, M., Zhang, R., et al . (2022) Reinfection in Patients with COVID-19: A Systematic Review. Global Health Research and Policy , 7, Article No. 12. https://doi.org/10.1186/s41256-022-00245-3
Rahman, S., Rahman, M.M., Miah, M., Begum, M.N., Sarmin, M., Mahfuz, M., et al . (2022) COVID-19 Reinfections among Naturally Infected and Vaccinated Individuals. Scientific Reports , 12, Article No. 1438. https://doi.org/10.1038/s41598-022-05325-5
Zhu, L., Xu, X., Zhu, B., Guo, X., Xu, K., Song, C., et al . (2021) Kinetics of Sars-Cov-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients. Microbiology Spectrum , 9, Article ID: 0059021. https://doi.org/10.1128/spectrum.00590-21
Anderson, E.J., Rouphael, N.G., Widge, A.T., Jackson, L.A., Roberts, P.C., Makhene, M., et al . (2020) Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine , 383, 2427-2438. https://doi.org/10.1056/nejmoa2028436
Mo, H., Zeng, G., Ren, X., Li, H., Ke, C., Tan, Y., et al . (2006) Longitudinal Profile of Antibodies against Sars-Coronavirus in SARS Patients and Their Clinical Significance. Respirology , 11, 49-53. https://doi.org/10.1111/j.1440-1843.2006.00783.x
Wu, L.P., Wang, N.C., Chang, Y.H., Tian, X.Y., Na, D.Y., Zhang, L.Y., et al . (2007) Duration of Antibody Responses after Severe Acute Respiratory Syndrome. Emerging Infectious Diseases , 13, 1562-1564. https://doi.org/10.3201/eid1310.070576
Organisation mondiale de la Santé (2021) Feuille de route du SAGE de l’OMS pour l’établissement des priorités concernant l’utilisation des vaccins anti-COVID-19: Approche visant à optimiser l’impact mondial des vaccins anti-COVID-19, Sur la base des objectifs de la santé publique, De l’équité au niveau mondial et national, Ainsi que des scénarios d’accessibilité des vaccins et de couverture vaccinale. https://www.who.int/europe/fr/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2021-1
Boniol, M., McIsaac, M., Xu, L., Wuliji, T., Diallo, K. and Campbell, J. (2019) Gender Equity in the Health Workforce: Analysis of 104 Countries Health Workforce Working Paper 1. OMS. https://www.researchgate.net/profile/Lihui-Xu-6/publication/372394388
Khanam, F., Langevin, M., Savage, K., Uppal, S. (2022) Les femmes occupant un emploi rémunéré dans les professions de soins à autrui. Statistics Canada, 25-26. https://publications.gc.ca/site/eng/9.907363/publication.html
Guiegui, C.P., Bremi, A.P., Aka, I.N.A., Kouame, B.A.A., Aholia, C., Kilanko, G.E., et al . (2022) Étude multicentrique du stress chez le personnel soignant des centres hospitalo-universitaires (CHU) d’Abidjan dans le contexte de la pandémie à Covid-19. Archives des Maladies Professionnelles et de l ’ Environnement , 83, 320-327. https://doi.org/10.1016/j.admp.2022.06.005
Cordioli, M., Mirandola, M., Gios, L., Gaspari, S., Carelli, M., Lotti, V., et al . (2022) COVID-19 Seroprevalence amongst Healthcare Workers: Potential Biases in Estimating Infection Prevalence. Epidemiology and Infection , 150, e48. https://doi.org/10.1017/s0950268822000280
Martinez-Alvarez, M., Jarde, A., Usuf, E., Brotherton, H., Bittaye, M., Samateh, A.L., et al . (2020) COVID-19 Pandemic in West Africa. The Lancet Global Health , 8, e631-e632. https://doi.org/10.1016/s2214-109x(20)30123-6
Assaid, N., Arich, S., Charoute, H., Akarid, K., Anouar Sadat, M., Maaroufi, A., et al . (2023) Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients. The American Journal of Tropical Medicine and Hygien e , 108, 145-154. https://doi.org/10.4269/ajtmh.22-0448
Gurgel, R.Q., de Sá, L.C., Souza, D.R.V., Martins, A.F., Matos, I.L.S., Lima, A.G.A., et al . (2021) Sars-Cov-2 Has Been Circulating in Northeastern Brazil since February 2020: Evidence for Antibody Detection in Asymptomatic Patients. Journal of Infection , 82, 186-230. https://doi.org/10.1016/j.jinf.2020.11.037
Trieu, M., Bansal, A., Madsen, A., Zhou, F., Sævik, M., Vahokoski, J., et al . (2020) Sars-Cov-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers after the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. The Journal of Infectious Diseases , 223, 589-599. https://doi.org/10.1093/infdis/jiaa737
Hashem, A.M., Algaissi, A., Almahboub, S.A., Alfaleh, M.A., Abujamel, T.S., Alamri, S.S., et al . (2020) Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients. Viruses , 12, Article No. 1390. https://doi.org/10.3390/v12121390
Li, K., Huang, B., Wu, M., Zhong, A., Li, L., Cai, Y., et al . (2020) Dynamic Changes in Anti-Sars-Cov-2 Antibodies during Sars-Cov-2 Infection and Recovery from Covid-19. Nature Communications , 11, Article No. 6044. https://doi.org/10.1038/s41467-020-19943-y
Hu, J.K., Crampton, J.C., Cupo, A., Ketas, T., van Gils, M.J., Sliepen, K., et al . (2015) Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. Journal of Virology , 89, 10383-10398. https://doi.org/10.1128/jvi.01653-15
Tam, H.H., Melo, M.B., Kang, M., Pelet, J.M., Ruda, V.M., Foley, M.H., et al . (2016) Sustained Antigen Availability during Germinal Center Initiation Enhances Antibody Responses to Vaccination. Proceedings of the National Academy of Sciences , 113, E6639-E6648. https://doi.org/10.1073/pnas.1606050113
Wheatley, A.K., Juno, J.A., Wang, J.J., Selva, K.J., Reynaldi, A., Tan, H., et al . (2021) Evolution of Immune Responses to Sars-Cov-2 in Mild-Moderate Covid-19. Nature Comm unications , 12, Article No. 1162. https://doi.org/10.1038/s41467-021-21444-5
Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., et al . (2021) Immunological Memory to Sars-Cov-2 Assessed for up to 8 Months after Infection. Science , 371, Article No. 4063. https://doi.org/10.1126/science.abf4063
Ebrahim, F., Tabal, S., Lamami, Y., Alhudiri, I.M., El Meshri, S.E., Al Dwigen, S., et a l . (2022) Anti-Sars-Cov-2 IgG Antibodies Post-Covid-19 or Post-Vaccination in Libyan Population: Comparison of Four Vaccines. Vaccines , 10, Article No. 2002. https://doi.org/10.3390/vaccines10122002
Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz-Tretyn, J., Sandomierz, D., Dejewska, J., et al . (2021) Differences in the Concentration of Anti-Sars-Cov-2 IgG Antibodies Post-Covid-19 Recovery or Post-Vaccination. Cells , 10, Article No. 1952. https://doi.org/10.3390/cells10081952
Anderson, E.M., Goodwin, E.C., Verma, A., Arevalo, C.P., Bolton, M.J., Weirick, M.E., et al . (2021) Seasonal Human Coronavirus Antibodies Are Boosted upon Sars-Cov-2 Infection but Not Associated with Protection. Cell , 184, 1858-1864.e10. https://doi.org/10.1016/j.cell.2021.02.010
Ng, K.W., Faulkner, N., Cornish, G.H., Rosa, A., Harvey, R., Hussain, S., et al . (2020) Preexisting and De Novo Humoral Immunity to Sars-Cov-2 in Humans. Science , 370, 1339-1343. https://doi.org/10.1126/science.abe1107
Jackson, L.A., Anderson, E.J., Rouphael, N.G., Roberts, P.C., Makhene, M., Coler, R.N., et al . (2020) An mRNA Vaccine against Sars-Cov-2—Preliminary Report. New Eng land Journal of Medicine , 383, 1920-1931. https://doi.org/10.1056/nejmoa2022483
Walsh, E.E., Frenck, R.W., Falsey, A.R., Kitchin, N., Absalon, J., Gurtman, A., et al . (2020) Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine , 383, 2439-2450. https://doi.org/10.1056/nejmoa2027906
Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., et al . (2021) Neutralizing Antibody Levels Are Highly Predictive of Immune Protection from Symptomatic Sars-Cov-2 Infection. Nature Medicine , 27, 1205-1211. https://doi.org/10.1038/s41591-021-01377-8
Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., Yang, D., Miller, T.E., Feldman, J., et al . (2021) Covid-19-Neutralizing Antibodies Predict Disease Severity and Survival. Cell , 184, 476-488.e11. https://doi.org/10.1016/j.cell.2020.12.015
Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., et al . (2021) Kinetics and Correlates of the Neutralizing Antibody Response to Sars-Cov-2 Infection in Humans. Cell Host & Microbe , 29, 917-929.e4. https://doi.org/10.1016/j.chom.2021.04.015
Betton, M., Livrozet, M., Planas, D., Fayol, A., Monel, B., Védie, B., et al . (2021) Sera Neutralizing Activities against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months after Hospitalization for Coronavirus Disease 2019. Clinical Infectious Diseases , 73, e1337-e1344. https://doi.org/10.1093/cid/ciab308
Noh, J.Y., Kwak, J., Yang, J., Hwang, S.Y., Yoon, J.G., Seong, H., et al . (2021) Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019. The Journal of Infectious Diseases , 224, 754-763. https://doi.org/10.1093/infdis/jiab124
Dispinseri, S., Secchi, M., Pirillo, M.F., Tolazzi, M., Borghi, M., Brigatti, C., et al . (2021) Neutralizing Antibody Responses to Sars-Cov-2 in Symptomatic COVID-19 Is Persistent and Critical for Survival. Nature Communications , 12, Article No. 2670. https://doi.org/10.1038/s41467-021-22958-8
Chia, W.N., Zhu, F., Ong, S.W.X., Young, B.E., Fong, S., Le Bert, N., et al . (2021) Dynamics of Sars-Cov-2 Neutralising Antibody Responses and Duration of Immunity: A Longitudinal Study. The Lancet Microbe , 2, e240-e249. https://doi.org/10.1016/s2666-5247(21)00025-2
Underwood, A.P., Sølund, C., Fernandez-Antunez, C., Villadsen, S.L., Mikkelsen, L.S., Fahnøe, U., et al . (2023) Durability and Breadth of Neutralisation Following Multiple Antigen Exposures to Sars-Cov-2 Infection and/or COVID-19 Vaccination. eBio Medicine , 89, Article ID: 104475. https://doi.org/10.1016/j.ebiom.2023.104475
Pradenas, E., Urrea, V., Marfil, S., Pidkova, T., Aguilar-Gurrieri, C., Abancó, F., et al . (2025) Recurrent Waning of Anti-Sars-Cov-2 Neutralizing Antibodies Despite Multiple Antigen Encounters. Journal of Translational Medicine , 23, Article No. 783. https://doi.org/10.1186/s12967-025-06837-0
Barnes, T.W., Schulte-Pelkum, J., Steller, L., Filchtinski, D., Jenness, R., Williams, M.R., et al . (2021) Determination of Neutralising Anti-Sars-Cov-2 Antibody Half-Life in COVID-19 Convalescent Donors. Clinical Immunology , 232, Article ID: 108871. https://doi.org/10.1016/j.clim.2021.108871
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K.J.A., et al . (2020) Longitudinal Observation and Decline of Neutralizing Antibody Responses in the Three Months Following Sars-Cov-2 Infection in Humans. Nature Microbiology , 5, 1598-1607. https://doi.org/10.1038/s41564-020-00813-8
Suthar, M.S., Zimmerman, M.G., Kauffman, R.C., Mantus, G., Linderman, S.L., Hudson, W.H., et al . (2020) Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Reports Medicine , 1, Article ID: 100040. https://doi.org/10.1016/j.xcrm.2020.100040
Walls, A.C., Sprouse, K.R., Bowen, J.E., Joshi, A., Franko, N., Navarro, M.J., et al . (2022) Sars-Cov-2 Breakthrough Infections Elicit Potent, Broad, and Durable Neutralizing Antibody Responses. Cell , 185, 872-880.e3. https://doi.org/10.1016/j.cell.2022.01.011
Rubio, R., Macià, D., Barrios, D., Vidal, M., Jiménez, A., Molinos-Albert, L.M., et al . (2025) High-Resolution Kinetics and Cellular Determinants of Sars-Cov-2 Antibody Response over Two Years after COVID-19 Vaccination. Microbes and Infection , 27, Article ID: 105423. https://doi.org/10.1016/j.micinf.2024.105423
Srivastava, K., Carreño, J.M., Gleason, C., Monahan, B., Singh, G., Abbad, A., et al . (2024) Sars-Cov-2-Infection-and Vaccine-Induced Antibody Responses Are Long Lasting with an Initial Waning Phase Followed by a Stabilization Phase. Immunity , 57, 587-599.e4. https://doi.org/10.1016/j.immuni.2024.01.017
Xiang, T., Liang, B., Fang, Y., Lu, S., Li, S., Wang, H., et al . (2021) Declining Levels of Neutralizing Antibodies against Sars-Cov-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset. Frontiers in Immunology , 12, Article ID: 708523. https://doi.org/10.3389/fimmu.2021.708523
Terpos, E., Stellas, D., Rosati, M., Sergentanis, T.N., Hu, X., Politou, M., et al . (2021) Sars-Cov-2 Antibody Kinetics Eight Months from COVID-19 Onset: Persistence of Spike Antibodies but Loss of Neutralizing Antibodies in 24% of Convalescent Plasma Donors. European Journal of Internal Medicine , 89, 87-96. https://doi.org/10.1016/j.ejim.2021.05.010